OncoMatch/Clinical Trials/NCT06690827
Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
Is NCT06690827 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Anti-CD123 CAR NK cells for aml (acute myeloid leukemia).
Treatment: Anti-CD123 CAR NK cells — This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: IL3RA positive expression (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: chemotherapy
Exception: except for those who have confirmed disease progression after treatment
Receipt of anti-tumor therapies prior to screening, including chemotherapy, targeted therapy, or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter), except for those who have confirmed disease progression after treatment
Cannot have received: targeted therapy
Exception: except for those who have confirmed disease progression after treatment
Receipt of anti-tumor therapies prior to screening, including chemotherapy, targeted therapy, or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter), except for those who have confirmed disease progression after treatment
Cannot have received: other experimental drug treatments
Exception: except for those who have confirmed disease progression after treatment
Receipt of anti-tumor therapies prior to screening, including chemotherapy, targeted therapy, or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter), except for those who have confirmed disease progression after treatment
Lab requirements
Blood counts
white blood cells >1.0×10^9/l, neutrophils >0.5×10^9/l, lymphocytes >0.5×10^9/l, platelets >50×10^9/l
Kidney function
serum creatinine ≤2.0×uln
Liver function
alt and ast ≤3.0×uln (for patients with liver invasion ≤5.0×uln); total bilirubin ≤2.0×uln (for patients with gilbert's syndrome ≤3.0×uln)
Cardiac function
echocardiography indicates a left ventricular ejection fraction ≥50%, and no significant abnormalities on electrocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06690827 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, targeted therapy, other experimental drug treatments disqualifies patients from enrollment.
Does this trial require IL3RA?
Yes, IL3RA positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages